Successful phenotype improvement following gene therapy for severe hemophilia a in privately owned dogs

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Callan, Mary Beth ^a   Haskins, Mark E ^a   Wang, Ping ^a   Zhou, Shangzhen ^b   High, Katherine A ^b,c,d   Arruda, Valder R ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Ophthalmology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DNA; METHIONINE; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; THREONINE;

ADULT; AMINO ACID SUBSTITUTION; ANTIBODY DETECTION; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 8 GENE; BLOOD CLOTTING PARAMETERS; CANINE MODEL; DISEASE SEVERITY; DOG; GENETIC ANALYSIS; HEMOPHILIA A; IMMUNE RESPONSE; MALE; MOLECULAR DIAGNOSIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TRANSLATIONAL RESEARCH; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADENOVIRIDAE; ANIMAL; DOG DISEASES; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; PET ANIMAL; PROCEDURES; THERAPEUTIC USE; VETERINARY;

ADENOVIRIDAE; ANIMALS; DOG DISEASES; DOGS; FACTOR VIII; FEMALE; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA A; MALE; PETS; PHENOTYPE;

EID: 84962097654     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151800     Document Type: Article

References (41)

1. Arruda V, High KA. Coagulation Disorders. In: Loscalzo J, Kasper D, HauserS, Fauci A, Jameson J, Longo D, eds. Harrison's Principles of Internal Medicine 19th Edition: McGraw Hill Education; 2015.
2. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol. 1999;105(4):1109-1113. PMID: 10554828
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N EnglJ Med. 2007;357(6):535-544. PMID: 17687129
4. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015;125(13):2038-2044. doi: 10.1182/blood-2015-01-528414 PMID: 25712992
5. Di Michele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost. 2002;87(1):52-57. PMID: 11848456
6. Hay CR, Di Michele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335-1344. doi: 10.1182/blood-2011-08-369132 PMID: 22101900
7. Gouw SC, van der Bom JG, Marijkevan den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648-4654. PMID: 17289808
8. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418-435. PMID: 12828678
9. Evatt BL, Robillard L. Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism. Haemophilia. 2000;6(3):131-134. PMID: 10792469
10. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJE, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347. PMID: 16474400
11. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002;99(8):2670-2676. PMID: 11929752
12. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N EnglJ Med. 2014;371(21):1994-2004. doi: 10.1056/NEJMoa1407309 PMID: 25409372
13. Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, Bellinger DA, et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR Journal. 2009;50(2):144-167. PMID: 19293459
14. Finn JD, Ozelo MC, Sabatino DE, Franck HWG, Merricks EP, Crudele JM, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. 2010;116(26):5842-5848. doi: 10.1182/blood-2010-06-288001 PMID: 20876851
15. McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013;121(17):3335-3344. doi: 10.1182/blood-2012-10-462200 PMID: 23426947
16. Sabatino DE, Lange AM, Altynova ES, Sarkar R, Zhou S, Merricks EP, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther. 2011;19(3):442-449. doi: 10.1038/mt.2010.240 PMID: 21081906
17. Siner JI, Iacobelli NP, Sabatino DE, Ivanciu L, Zhou S, Poncz M, et al. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood. 2013;121(21):4396-4403. doi: 10.1182/blood-2012-10-464164 PMID: 23372167
18. Nair N, Rincon MY, Evens H, Evens H, Sarcar S, Dastidar S, et al. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood. 2014;123(20):3195-3199. doi: 10.1182/blood-2013-10-534032 PMID: 24637359
19. Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. Development offactor VIII: C antibodies in dogs with hemophilia A (factor VIII: C deficiency). Blood. 1984;63(2):451-456. PMID: 6419797
20. Sabatino DE, Freguia CF, Toso R, Andrey Santos A, Merricks EP, Kazazian HH Jr, et al. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood. 2009;114(20):4562-4565. doi: 10.1182/blood-2009-05-220327 PMID: 19770361
21. Mingozzi F, Anguela XM, Pavani G, Chen Y, Davidson RJ, Hui DJ, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. SciTransl Med. 2013;5(194):194ra192.
22. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood. 2006;108(10):3321-3328. PMID: 16868252
23. Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther. 2011;22(11):1389-1401. doi: 10.1089/hum.2011.031 PMID: 21476868
24. Crudele JM, Finn JD, Siner JI, Martin NB, Niemeyer GP, Zhou S, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood. 2015;125(10):1553-1561. doi: 10.1182/blood-2014-07-588194 PMID: 25568350
25. Booth CJ, Brooks MB, Rockwell S, Murphy JW, Rinder HM, Zelterman D, et al. WAG-F8 (m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. JThromb Haemost. 2010;8(11):2472-2477. doi: 10.1111/j.1538-7836.2010.03978.x PMID: 20626616
26. Porada CD, Sanada C, Long CR, Wood A, Desai J, Frederick N, et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. JThromb Haemost. 2010;8(2):276-285. doi: 10.1111/j.1538-7836.2009.03697.x PMID: 19943872
27. Mao J, Xi X, Kapranov P, Dong B, Firrman J, Xu R, et al. and Model Systems for Hemophilia A Gene Therapy. J Genet Syndr Gene Ther. 2013; Suppl 1:.
28. de Brasi C, El-Maarri O, Perry DJ, Oldenburg J, Pezeshkpoor B, Goodeve A. Genetic testing in bleeding disorders. Haemophilia. 2014;20 Suppl 4:54-58. doi: 10.1111/hae.12409 PMID: 24762276
29. Rost S, Loffler S, Pavlova A, Muller CR, Oldenburg J. Detection of large duplications within the factor VIII gene by MLPA. JThromb Haemost. 2008;6(11):1996-1999. doi: 10.1111/j.1538-7836.2008. 03125.x PMID: 18752578
30. Hough C, Kamisue S, Cameron C, Notley C, Tinlin S, Giles A, et al. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. Thromb Haemost. 2002;87(4):659-665. PMID: 12008949
31. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, et al. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proc Natl Acad Sci USA. 2002;99(20):12991-12996. PMID: 12242334
32. Nichols TC, Whitford MH, Arruda VR, Stedman HH, Kay MA, High KA. Translational data from adenoassociated virus-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev. 2015;26(1):5-14. doi: 10.1089/humc.2014.153 PMID: 25675273
33. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 2009;113(4):797-806. doi: 10.1182/blood-2008-10-181479 PMID: 18957684
34. Demaster A, Luo X, Curtis S, Williams KD, Landau DJ, Drake EJ, et al. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia. Hum Gene Ther. 2012;23(4):407-418. doi: 10.1089/hum.2011.106 PMID: 22185325
35. Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther. 2012;19(3):288-294. doi: 10.1038/gt.2011.90 PMID: 21697954
36. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther. 2010;21(6):704-712. doi: 10.1089/hum.2009.182 PMID: 20095819
37. Calcedo R, Wilson JM. Humoral Immune Response to AAV. Front Immunol. 2013;4:341. doi: 10.3389/fimmu.2013.00341 PMID: 24151496
38. Masat E, Pavani G, Mingozzi F. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med. 2013;15(85):379-389. PMID: 23819952
39. Mingozzi F, Chen Y, Edmonson SC, Zhou S, Thurlings RM, Tak PP, et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther. 2013;20(4):417-424. doi: 10.1038/gt.2012.55 PMID: 22786533
40. Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM, et al. Selection and evaluation of clinically relevant AAV variants in axenograft liver model. Nature. 2014;506(7488):382-386. doi: 10. 1038/nature12875 PMID: 24390344
41. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19(5):876-885. doi: 10.1038/mt. 2010.274 PMID: 21245849